Your Health, We Care
Ivosidenib is indicated for patients whose susceptible isocitrate dehydrogenase-1 (IDH1) mutation has been detected using an FDA-approved test. The specific indications are as follows:
1. Newly Diagnosed Acute Myeloid Leukemia (AML)
In combination with azacitidine, or as monotherapy, for adult patients aged ≥75 years with newly diagnosed AML, or for adult patients with newly diagnosed AML who have comorbidities that preclude the use of intensive induction chemotherapy.
2. Relapsed or Refractory Acute Myeloid Leukemia (AML)
For the treatment of adult patients with relapsed or refractory AML.
3. Relapsed or Refractory Myelodysplastic Syndromes (MDS)
For the treatment of adult patients with relapsed or refractory myelodysplastic syndromes.
4. Locally Advanced or Metastatic Cholangiocarcinoma
For the treatment of adult patients with previously treated locally advanced or metastatic cholangiocarcinoma.
from FDA，2023.10
Ivosidenib is the first approved drug of the IDH1 inhibitor class. It works by inhibiting isocitrate···【more】
Recommended：422025-31-12
Ivosidenib targets a specific gene mutation called IDH1, which may affect your bone marrow.What are ···【more】
Recommended：242025-31-12
It is indicated for patients with susceptible isocitrate dehydrogenase-1 (IDH1) mutations confirmed by a test method approved by the FDA.【more】
Article source：Lucius LaosRelease date：2026-01-06Recommended：15
Ivosidenib is the first approved drug of the IDH1 inhibitor class. It works by inhibiting isocitrate dehydrogenase-1 (IDH1) to reduce the abnormal production of 2-hydroxyglutarate ···【more】
Article source：Lucius LaosRelease date：2025-12-31Recommended：42
Ivosidenib targets a specific gene mutation called IDH1, which may affect your bone marrow.What are the indications for Ivosidenib?The IDH1 mutation impairs the development of imma···【more】
Article source：Lucius LaosRelease date：2025-12-31Recommended：24
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
